Scientist II, Bioassay DevelopmentBe BiopharmaCambridge, Massachusetts, United States
OC 11.3 - Development of BE-101, an autologous ex vivo precision gene engineered B cell medicine that produces active and sustained levels of factor IX for the treatment of hemophilia B
Sunday, June 23, 202410:00 – 10:15 ICT
